Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group

Fig. 2

Monotherapies (Mono) and combinations of immunosuppressants ever used, percentages are based on the number of patients. Treatment regimens with frequencies <0.5% were omitted. GC glucocorticoids, CYC cyclophosphamide, AZA azathioprine, MTX methotrexate, MMF mycophenolate mofetil, RTX rituximab, DPA D-penicillamine, a-TNF anti-tumour necrosis factor, IMA imatinib

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us